Modifying PEST for Psoriatic Arthritis Screening

Key facts

Sponsor

Novartis Pharmaceuticals

Principal Investigator

Novartis Pharmaceuticals

Novartis Pharmaceuticals

Intervention

PEST Screening group(diagnostic_test)

Enrollment

502 target

Eligibility

18 years · All sexes

Timeline

2025 – 2026

Study locations (12)

• Novartis Investigative Site, Kelowna, British Columbia, Canada
• Novartis Investigative Site, Surrey, British Columbia, Canada
• Novartis Investigative Site, Fredericton, New Brunswick, Canada
• Novartis Investigative Site, Hamilton, Ontario, Canada
• Novartis Investigative Site, Markham, Ontario, Canada
• Novartis Investigative Site, Richmond Hill, Ontario, Canada
• Novartis Investigative Site, Stoney Creek, Ontario, Canada
• Novartis Investigative Site, Waterloo, Ontario, Canada
• Novartis Investigative Site, Montreal, Quebec, Canada
• Novartis Investigative Site, Québec, Quebec, Canada
• Novartis Investigative Site, Ste-Foy, Quebec, Canada
• Novartis Investigative Site, Saskatoon, Saskatchewan, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for NON RARE IN EUROPE: Psoriatic arthritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07290036
  A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
  UCB Biopharma SRL
• RECRUITINGPHASE2NCT06176508
  Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
  Hansoh BioMedical R&D Company
• ENROLLING BY INVITATIONNANCT06176586
  Mat Pilates Exercise Program in Patients With Axial Psoriatic Arthritis
  Izmir Katip Celebi University
• RECRUITINGNCT06437392
  Evaluation of Sarcopenia and Related Factors in Patients Diagnosed With Psoriatic Arthritis
  Ankara City Hospital Bilkent
• RECRUITINGNCT07277491
  Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
  Cairo University
• ACTIVE NOT RECRUITINGPHASE3NCT04908189
  A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
  Bristol-Myers Squibb
• RECRUITINGNCT03768271
  APACHE Cohort (A Psoriatic Arthritis CoHort)
  Assistance Publique - Hôpitaux de Paris
• ACTIVE NOT RECRUITINGPHASE3NCT03671148
  A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
  AbbVie

See all trials for NON RARE IN EUROPE: Psoriatic arthritis →